Iqvia Institute for Human Data Science says that over the next five years, clinical trial productivity will be heavily influenced by trends like biomarkers, pre-screened patient pools, and predictive analytics. The projection is in a white paper, “The Changing Landscape of Research and Development.”
The analysis indicates that ongoing changes in the clinical development process led to a record number of drug approvals in 2018, with 59 novel treatments reaching patients in the U.S. alone.
The study assesses the current activity within research and development, the productivity levels of the clinical development process, and how key trial trends will transform clinical development over the next five years.
Key sections of the report look at new drug approvals and launches, clinical development pipeline, clinical trial activity, drivers of change in clinical development, and modeling future trial productivity.